Natco Pharma Q1 Results FY26: Q1 PAT Falls 28.09% to ₹480.70 Crore; Revenue Down 2.47% YoY

Natco Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹1,328.90	₹1,362.60
Profit Before Tax (PBT)	₹632.70	₹852.90
Profit After Tax (PAT)	₹480.70	₹668.50

(Figures in crores)

Natco Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹1,192.70	₹1,236.90
Profit Before Tax (PBT)	₹599.30	₹802.80
Profit After Tax (PAT)	₹464.10	₹636.30

(Figures in crores)

Natco Pharma Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Natco Pharma clocked Q1 FY26 consolidated revenue of ₹1,328.90 crores vs ₹1,362.60 crores. 
• On the profit front, Natco Pharma earned a consolidated PAT of ₹480.70 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹668.50 crore. 
• Consolidated PAT fell for the first quarter of FY26, was 28.09% YoY, and revenue fell 2.47% YoY. 
• As per the standalone figures, the quarterly PAT of Natco Pharma has decreased by 27.06%, and revenue has decreased by 3.57% YoY.

Natco Pharma Share Price Performance

On the opening bell of 12th August 2025, the shares of Natco Pharma opened at ₹901.05 per share. However, the initial gains are wiped out as of now, and Natco Pharma shares are trading at ₹887.80 per share, lower than their opening price. 

Considering the long-term performance, Natco Pharma shares have yielded close to -40.60% returns in the past 1 year, and 5-year returns stand at 7.02%. Over the maximum timeframe, the Natco Pharmashare provided 24,979.10% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Natco Pharma shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

HBL Engineering Q1 Results FY26: Q1 PAT Rises 78.87% to ₹143.27 Crore; Revenue Up 15.70% YoY

Fine Organic Q1 Results FY26: Q1 PAT Rose 7.04% to ₹117.10 Crore; Revenue Up 7.04% YoY

Eureka Forbes Q1 Results FY26: Q1 PAT Rises 20.32% to ₹38.68 Crore; Revenue Up 9.85% YoY

JM Financial Q1 Results FY26: Q1 PAT Rose 165.85% to ₹453.81 Crore; Revenue Up 3.18% YoY

IPCA Laboratories Q1 Results FY26: Q1 PAT Rises 21.31% to ₹233.21 Crore; Revenue Up 10.33% YoY